Oric Pharmaceuticals Inc Asset Resilience Ratio
Oric Pharmaceuticals Inc asset resilience ratio. Oric Pharmaceuticals Inc (ORIC) has an Asset Resilience Ratio of 56.16% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Oric Pharmaceuticals Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Oric Pharmaceuticals Inc (2020–2025)
Asset resilience ratio of Oric Pharmaceuticals Inc from 2020 to 2025. This chart shows how Oric Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Read Oric Pharmaceuticals Inc (ORIC) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Oric Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Oric Pharmaceuticals Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $227.28 Million | 56.16% |
| Total Liquid Assets | $227.28 Million | 56.16% |
Asset Resilience Insights
- Very High Liquidity: Oric Pharmaceuticals Inc maintains exceptional liquid asset reserves at 56.16% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Oric Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Oric Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Oric Pharmaceuticals Inc Asset Resilience Ratio by Year (2020–2025)
Oric Pharmaceuticals Inc asset resilience ratio by year from 2020 to 2025. The table below shows the annual Asset Resilience Ratio data for Oric Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 57.38% | $235.82 Million | $411.00 Million | -14.32pp |
| 2024-12-31 | 71.70% | $196.55 Million | $274.14 Million | -0.86pp |
| 2023-12-31 | 72.56% | $184.80 Million | $254.69 Million | +16.87pp |
| 2022-12-31 | 55.69% | $139.43 Million | $250.36 Million | +52.02pp |
| 2021-12-31 | 3.67% | $10.97 Million | $298.64 Million | -68.28pp |
| 2020-12-31 | 71.96% | $215.15 Million | $299.00 Million | -- |
About Oric Pharmaceuticals Inc
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target… Read more